S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

$24.68
-0.84 (-3.29%)
(As of 03/28/2024 ET)
Today's Range
$24.21
$25.75
50-Day Range
$13.50
$27.34
52-Week Range
$4.44
$30.96
Volume
1.26 million shs
Average Volume
589,994 shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.50

Immunome MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.7% Downside
$24.50 Price Target
Short Interest
Healthy
4.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of Immunome in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.97) to ($1.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.62 out of 5 stars

Medical Sector

861st out of 939 stocks

Pharmaceutical Preparations Industry

405th out of 441 stocks

IMNM stock logo

About Immunome Stock (NASDAQ:IMNM)

Immunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

IMNM Stock Price History

IMNM Stock News Headlines

TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Immunome (NASDAQ:IMNM) Shares Gap Up to $24.14
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Immunome Stock (NASDAQ:IMNM), Short Interest Report
IMNM Apr 2024 30.000 call
IMNM Mar 2024 10.000 put
IMNM Jul 2024 25.000 put
IMNM Mar 2024 20.000 put
IMNM Apr 2024 12.500 put
IMNM Apr 2024 7.500 call
IMNM Mar 2024 22.500 put
See More Headlines
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMNM
Fax
N/A
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.50
High Stock Price Target
$30.00
Low Stock Price Target
$19.00
Potential Upside/Downside
-0.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-36,900,000.00
Pretax Margin
-215.44%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.37 per share

Miscellaneous

Free Float
43,802,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
1.67
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Clay B. Siegall Ph.D. (Age 63)
    President, CEO & Chairman
  • Mr. Max Rosett (Age 34)
    Interim CFO & Executive VP of Operations
  • Mr. Robert Lapetina (Age 49)
    Principal Accounting Officer
  • Mr. Philip Roberts
    Chief Technical Officer
  • Dr. Jack Higgins Ph.D. (Age 44)
    Chief Scientific Officer
  • Ms. Sandra G. Stoneman Esq. (Age 51)
    J.D., Chief Legal Officer, General Counsel & Corporate Secretary
    Comp: $443.43k
  • Mr. Bruce Turner M.D. (Age 61)
    Ph.D., Chief Strategy Officer
  • Dr. Robert J. Lechleider M.D.
    Chief Medical Officer
  • Mr. Kinney Horn (Age 49)
    Chief Business Officer

IMNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunome stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMNM shares.
View IMNM analyst ratings
or view top-rated stocks.

What is Immunome's stock price target for 2024?

5 Wall Street research analysts have issued 12 month price targets for Immunome's stock. Their IMNM share price targets range from $19.00 to $30.00. On average, they anticipate the company's stock price to reach $24.50 in the next twelve months. This suggests that the stock has a possible downside of 0.7%.
View analysts price targets for IMNM
or view top-rated stocks among Wall Street analysts.

How have IMNM shares performed in 2024?

Immunome's stock was trading at $10.70 at the beginning of the year. Since then, IMNM shares have increased by 130.7% and is now trading at $24.68.
View the best growth stocks for 2024 here
.

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14.

When did Immunome IPO?

Immunome (IMNM) raised $30 million in an IPO on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO.

Who are Immunome's major shareholders?

Immunome's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.07%), Vanguard Group Inc. (3.18%), Avidity Partners Management LP (3.12%), Price T Rowe Associates Inc. MD (2.46%), Price T Rowe Associates Inc. MD (2.46%) and Point72 Asset Management L.P. (1.60%). Insiders that own company stock include Bruce Turner, Clay B Siegall, Michael Lefenfeld, Michael Rapp and Purnanand D Sarma.
View institutional ownership trends
.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMNM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners